With our services, we assist the pharmaceutical, biotech and academic communities from early preclinical research, including in vivo models, through large-scale, late-stage clinical trial programs for vaccines, monoclonal antibodies, and antivirals. In our BSL3 containment laboratories, we offer fully validated assays, targeting highly pathogenic viruses.
We offer a wide range of preclinical models, virological, molecular, and immunological assays. In addition, we offer a full suite of global logistics services.
With our inhouse R&D services we are expertise in developing and validating new assays, improving existing assays and implementing customer assays. Highly customized solutions are available including novel assay platforms such as The VirospotTM (trademark).
The assay platform has been developed for the detection and phenotypic characterization of influenza viruses in phase 2 and phase 3 clinical trials of new antiviral compounds. It combines classic virus culture techniques with automated sensitive detection of immunostained virus infected cells and is now also available in a format for antigenic characterization of influenza A(H3N2) viruses.